Publications by authors named "D Rhainds"
Article Synopsis
- Myo-inositol is elevated in patients with heart failure (HF), particularly in those with heart failure with preserved ejection fraction (HFpEF), and is associated with negative clinical outcomes.
- The study measured plasmatic myo-inositol levels in large cohorts from Belgium and Canada, revealing significant increases in HF patients compared to those without.
- Elevated myo-inositol levels correlate with worsening kidney function and cardiac markers, suggesting a potential role in the development and progression of HFpEF.
Article Synopsis
- Genetic variants in drug targets, specifically CETP, can help predict how sex and body mass index (BMI) impact drug effects on cardiovascular health.
- In a study with UK Biobank participants, it was found that women and those with lower BMI had more favorable lipid profiles linked to genetically lower CETP levels.
- While sex affected some lipid-related outcomes, it didn't influence cardiovascular outcomes, suggesting the need for personalized medicine approaches based on genetic factors.
The large HDL particles generated by administration of cholesteryl ester transfer protein inhibitors (CETPi) remain poorly characterized, despite their potential importance in the routing of cholesterol to the liver for excretion, which is the last step of the reverse cholesterol transport. Thus, the effects of the CETPi dalcetrapib and anacetrapib on HDL particle composition were studied in rabbits and humans. The association of rabbit HDL to the LDL receptor (LDLr) in vitro was also evaluated.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated how low-dose colchicine affects inflammation, specifically looking at high-sensitivity C reactive protein (hs-CRP) levels in patients after an acute myocardial infarction.
- - Analysis of data from two clinical trials (COLCOT and LoDoCo-MI) found no significant change in hs-CRP levels when measured continuously, but colchicine did increase the likelihood of patients achieving low hs-CRP levels (≤1.0 mg/L).
- - The findings suggest that reducing inflammation might play a crucial role in colchicine's effectiveness in preventing further cardiovascular events post-heart attack, highlighting the importance of monitoring hs-CRP levels during treatment.
Aims: The adenylate cyclase type 9 (ADCY9) gene appears to determine atherosclerotic outcomes in patients treated with dalcetrapib. In mice, we recently demonstrated that Adcy9 inactivation potentiates endothelial function and inhibits atherogenesis. The objective of this study was to characterize the contribution of ADCY9 to the regulation of endothelial signalling pathways involved in atherosclerosis.
View Article and Find Full Text PDF